Inverness Medical Innovations
This article was originally published in The Gray Sheet
Executive Summary
$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...